Cost Effectiveness of Using DPP-4i and SGLT2i Combination Therapy vs. Switching to GLP-1 Therapy for the Management of Type 2 Diabetes

被引：0
|
作者：
Pawaskar, Manjiri
Bilir, S. Pinar
Davies, Glenn M.
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-1275-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1275-P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Cost Effectiveness of DPP-4i and SGLT2i Combination Therapy for the Treatment of Type 2 Diabetes in the US
    Pawaskar, Manjiri
    Bilir, S. Pinar
    Graber-Naidich, Anna
    Gonzalez, Claudio D.
    Rajpathak, Swapnil
    Davies, Glenn M.
    DIABETES, 2018, 67
  • [2] Early combination therapy with SGLT2i and GLP-1 RA or dual GIP/GLP-1 RA in type 2 diabetes
    Vale, Catarina
    Lourenco, Ines Mariana
    Jordan, Gabriela
    Golovaty, Ilya
    Torres, Hugo
    Moin, Tannaz
    Buysschaert, Martin
    Neves, Joao Sergio
    Bergman, Michael
    DIABETES OBESITY & METABOLISM, 2024,
  • [3] Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA
    Zornitsa Mitkova
    Konstantin Mitov
    Vasil Valov
    Manoela Manova
    Alexandra Savova
    Maria Kamusheva
    Dimitar Tcharaktchiev
    Zhivko Angelov
    Galia Angelova
    Guenka Petrova
    International Journal of Diabetes in Developing Countries, 2018, 38 : 520 - 521
  • [4] Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA
    Mitkova, Zornitsa
    Mitov, Konstantin
    Valov, Vasil
    Manova, Manoela
    Savova, Alexandra
    Kamusheva, Maria
    Tcharaktchiev, Dimitar
    Angelov, Zhivko
    Angelova, Galia
    Petrova, Guenka
    INTERNATIONAL JOURNAL OF DIABETES IN DEVELOPING COUNTRIES, 2018, 38 (04) : 520 - 521
  • [5] Benefit of dual therapy with GLP-1 RA and SGLT2i on cardiovascular outcomes in type 2 diabetes
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Clemmensen, K. K. B.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S30 - S30
  • [6] Benefit of dual therapy with GLP-1 RA and SGLT2i on renal outcomes in type 2 diabetes
    Clemmensen, K. K. B.
    Zareini, B.
    Gerds, T.
    Sorensen, K. K.
    Kvist, K.
    David, J. -P.
    Torp-Pedersen, C.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S29 - S29
  • [7] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Cardiovascular Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
  • [8] Benefit of Dual Therapy with GLP-1 RA and SGLT2i on Renal Outcomes in Type 2 Diabetes
    Zareini, Bochra
    Gerds, Thomas A.
    Sorensen, Kathrine K.
    Clemmensen, Kim K. B.
    Kvist, Kajsa
    David, Jens-Peter
    Torp-Pedersen, Christian
    DIABETES, 2023, 72
  • [9] Stroke, acute myocardial infarction and mortality in type 2 diabetes: a nationwide comparative effectiveness study of GLP-1RA, SGLT2i and DPP-4i treatment
    Hastrup, S.
    Hedegaard, J.
    Andersen, G.
    Osler, M.
    Rungby, J.
    Johnsen, S.
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S345 - S346
  • [10] Effect of SGLT2i, DPP-4i, and the Combination of SGLT2i+DPP-4i on Glucagon, Endogenous Glucose Production (EGP), and Lipolysis in Patients with Type 2 Diabetes (T2DM)
    Sach-Friedl, Stefanie
    Augustin, Thomas
    Magnes, Christoph
    Ekardt, Eva
    Eberl, Anita
    Narath, Sophie
    Brunner, Martina
    Korsatko, Stefan
    Svehlikova, Eva
    Treiber, Gerlies
    Pieber, Thomas
    DIABETES, 2017, 66 : A312 - A312
12345